Ocular Imaging With Spectral Domain Optical Coherence Tomography

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2009 by Yonsei University.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Yonsei University
ClinicalTrials.gov Identifier:
NCT00926549
First received: May 6, 2009
Last updated: June 19, 2009
Last verified: June 2009
  Purpose

The purpose of this study is to analyze macular retinal thickness and macular volume using the spectral domain - optical coherence tomography (SD-OCT) in normal eyes and in eyes with various ocular diseases.


Condition Intervention
Healthy
Myopia
Hypermetropia
Device: Spectral domain-OCT (Cirrus™ HD-OCT, Carl Zeiss Meditec AG)

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Posterior and Anterior Ocular Imaging With Spectral Domain Optical Coherence Tomography

Further study details as provided by Yonsei University:

Primary Outcome Measures:
  • macular retinal thickness and volume [ Time Frame: 3 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 300
Study Start Date: May 2009
Estimated Study Completion Date: September 2009
Estimated Primary Completion Date: September 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: spectral domain-OCT
Spectral domain-OCT scanning performed.
Device: Spectral domain-OCT (Cirrus™ HD-OCT, Carl Zeiss Meditec AG)
macular cube scanning
Other Name: Cirrus™ HD-OCT, Carl Zeiss Meditec AG

Detailed Description:

Assessment of macular thickness is important for the treatment and follow-up of a variety of ocular diseases. The introduction of optical coherence tomography (OCT) has enabled clinicians to reliably detect small changes in macular thickness and to quantitatively evaluate the efficacy of different therapeutic modalities. In this study using the spectral domain-OCT, we examined the variations of macular retinal thickness and macular volume in normal eyes and in eyes with various ocular diseases.

  Eligibility

Ages Eligible for Study:   16 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • normal eyes
  • myopic eyes
  • hypermetropic eyes

Exclusion Criteria:

  • systemic illness
  • cataract
  • previous ocular trauma or surgery(other than cataract surgery or refractive surgeries)
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00926549

Contacts
Contact: Sung Soo Kim, MD, PhD 82-2-2019-3443 semekim@naver.com
Contact: Won Kyung Song, MD 82-2-2228-3591 songwk@yuhs.ac

Locations
Korea, Republic of
Yonsei University College of Medicine, Gangnam Severance Hospital Recruiting
Seoul, Korea, Republic of, 135-720
Contact: Sung Soo Kim, MD, PhD    82-2-2019-3443    semekim@naver.com   
Contact: Won Kyung Song, MD    82-2-2228-3591    songwk@yuhs.ac   
Principal Investigator: Sung Soo Kim, MD, PhD         
Sponsors and Collaborators
Yonsei University
Investigators
Principal Investigator: Sung Soo Kim, MD, PhD Department of Ophthalmology, Yonsei University College of Medicine, Gangnam Severance Hospital
  More Information

No publications provided

Responsible Party: Sung Soo Kim, Department of Ophthalmology, Gangnam Severance Hospital
ClinicalTrials.gov Identifier: NCT00926549     History of Changes
Other Study ID Numbers: 3-2008-0048
Study First Received: May 6, 2009
Last Updated: June 19, 2009
Health Authority: Korea: Food and Drug Administration

Keywords provided by Yonsei University:
spectral domain-OCT
macular thickness
myopia
hypermetropia
normal

Additional relevant MeSH terms:
Hyperopia
Myopia
Refractive Errors
Eye Diseases

ClinicalTrials.gov processed this record on April 23, 2014